113 pages, November 2018
About this market
With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins. For instance, Allergan, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX Reimbursement Solutions Program. This program includes a BOTOX Hotline and BOTOX Patient Assistance Program to assist patients who are receiving BOTOX injection treatment. Analysts have predicted that the cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.
Market Overview
Expected approval of late-stage pipeline molecules
The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia. The cervical dystonia therapeutics market is also expected to benefit from the growing number of molecules being launched for the treatment of the disease.
Availability of alternate therapies
For the treatment of cervical dystonia, botulinum toxins and other therapeutics are used. However, the low rate of success and temporary cure of these therapeutics leads people towards alternative therapies such as DBS surgery, which is a major challenge for the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the cervical dystonia therapeutics market during the 2019-2023 period, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Allergan and Eisai, the competitive environment is quite intense. Factors such as the rising number of reimbursement programs for botulinum neurotoxin injections and the anticipated approval of late-stage pipeline molecules, will provide considerable growth opportunities to cervical dystonia therapeutic vendors. Allergan, Eisai, Ipsen Pharma, Merz Pharma, and US WorldMeds are some of the major companies covered in this report.